Meta-analysis of Efficacy of Curcumin in the Treatment of Complications of Type Ⅱ Diabetes Mellitus
ZHENG Zi-hui1, PAN Hui-jie2, ZHAO Zi-nan1, YUAN Hua1, LI Wen-ying1, ZHANG Bai-ge1, MA Lin1, JING Peng-fei1*
1. Department of Pharmacy,National Center of Gerontology,Chinese Academy of Medical Sciences, Institute of Geriatric Medicine, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital), Beijing Hospital, Beijing 100730, China; 2. Clinical laboratory, National Center of Gerontology, Chinese Academy of Medical Sciences, Institute of Geriatric Medicine, Beijing Hospital, Beijing 100730, China
Abstract：OBJECTIVE To evaluate systematically the efficacy of curcumin in the treatment of type Ⅱ diabetes mellitus(T2DM). METHODS The Cochrane Library, PubMed, Embase, CNKI, Wanfang Data, and The China Biomedical Data Database(CMB)were retrieved until December 2020.The randomized controlled trials(RCTs)evaluating curcumin for T2DM were included.After selecting the literature according to the inclusion and exclusion criteria, extracting the data and evaluating the methodological quality of the included studies, the Revman 5.4 software was used for Meta analysis. RESULTS A total of 8 RCTs were included in the analysis, including 531 patients with 267 in the experimental group and 264 in the control group. In addition to the basic treatment, patients in the treatment group were given curcumin, while patients in the control group were given a placebo.Outcome measures included triglycerides(TG), total cholesterol(TC), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), body mass index(BMI), fasting blood glucose(FBG) and glycosylated hemoglobin(HbA1c). RESULTS showed that there were significant differences in TG(MD=-13.99, 95%CI:-26.91--1.07, P=0.03＜0.05), TC(MD=-11.30, 95%CI:-20.69--1.91, P=0.02＜0.05), HDL-C(MD＝2.92, 95%CI: 1.65-4.19, P＜0.01), LDL-C(MD=-11.19, 95%CI:-19.54--2.84, P＜0.01), BMI(MD=-1.75, 95%CI:-2.23--1.27, P＜0.01), FBG(MD=-14.49, 95%CI:-21.20--7.79, P＜0.01) and HbA1c(MD=-0.85, 95%CI:-1.16--0.54, P＜0.01). CONCLUSION Curcumin can effectively improve multiple biochemical indexes in patients with type 2 diabetes and reduce the risk of cardiovascular and cerebrovascular diseases.
郑子恢, 潘慧杰, 赵紫楠, 袁华, 李文英, 张白鸽, 马琳, 金鹏飞. 姜黄素治疗2型糖尿病并发症有效性的Meta分析[J]. 中国药学杂志, 2021, 56(6): 489-496.
ZHENG Zi-hui, PAN Hui-jie, ZHAO Zi-nan, YUAN Hua, LI Wen-ying, ZHANG Bai-ge, MA Lin, JING Peng-fei. Meta-analysis of Efficacy of Curcumin in the Treatment of Complications of Type Ⅱ Diabetes Mellitus. Chinese Pharmaceutical Journal, 2021, 56(6): 489-496.
KHANDOUZI N, SHIDFAR F, RAJAB A, et al. The effects of ginger on fasting blood sugar, hemoglobin a1c, apolipoprotein B, apolipoprotein a-I and malondialdehyde in type 2 diabetic patients[J]. Iran J Pharm Res, 2015, 14 (1): 131-140.
[2]
RIVERA-MANCIA S, LOZADA-GARCIA M C, PEDRAZA-CHAVERRI J. Experimental evidence for curcumin and its analogs for management of diabetes mellitus and its associated complications[J]. Eur J Pharmacol, 2015, 756: 30-37.
[3]
ARUN N, NALINI N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats[J]. Plant Foods Human Nutr, 2002, 57 (1): 41-52.
[4]
ZHONG Q Q, ZHU L Y, ZHANG G G, et al. Explanation of ESC 2019 guidelines on diabetes,pre-diabetes and cardiovascular diseases[J]. Chin J Cardiov Res (中国心血管病研究), 2019, 17(10):881-883.
[5]
ALI HUSSAIN H E. Hypoglycemic, hypolipidemic and antioxidant properties of combination of curcumin from Curcuma longa Linn, and partially purified product from Abroma augusta Linn. in streptozotocin induced diabetes[J]. Indian J Clin Biochem, 2002,17(2):33-43.
[6]
TAN K. Dyslipidaemia, Amsterdam: Dysfunction in Diabetes Mellitus. Vol1262[M]. Amsterdam: International Congress Series, 2004: 511-514.
[7]
World Health Organization. Global report on diabetes[R]. World Health Organization, 2016: 20-31.
[8]
ZAHID ASHRAF M, HUSSAIN M E, FAHIM M. Antiatherosclerotic effects of dietary supplementations of garlic and turmeric: restoration of endothelial function in rats[J]. Life Sci, 2005, 77 (8):837-857.
[9]
The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. version 5.1.0[EB/OL]. [2019-04-26]. 2011-03. http: ∥ www.cochrane.org/.
[10]
ADIBIAN M, HODAEI H, NIKPAYAM O, et al. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial[J]. Phytother Res, 2019, 33(5): 1374-1383.
[11]
ASADI S, GHOLAMI M S, SIASSI F, et al. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled clinical trial [J]. Comp Ther Med, 2019, 43: 253-260.
[12]
FUNAMOTO M, SHIMIZU K, SUNAGAWA Y, et al. Effects of highly absorbable curcumin in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus[J]. J Diabetes Res, 2019: Article ID: 8208237.
[13]
KHAJEHDEHI P, PAKFETRAT M, JAVIDNIA K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study[J]. Scand J Urol Nephrol, 2011, 45(5): 365-370.
[14]
NA L X, LI Y ,PAN H Z, et al. Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial[J]. Mol Nutr Food Res, 2013, 57(9): 1569-1577.
[15]
PANAHI Y, KHALILI N, SAHEBI E, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial[J]. Comp Ther Med, 2017, 33: 1-5.
[16]
PANAHI Y, KHALILI N, SAHEBI E, et al. Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial[J]. Drug Res (Stuttg), 2018, 68(7): 403-409.
[17]
USHARANI P, MATEEN A A, NAIDU M U R, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study[J]. Drugs Res Dev, 2008, 9(4): 243-250.
[18]
AGGARWAL B B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals[J]. Annu Rev Nutr, 2010, 30:173-199.
[19]
WEISBERG S P, LEIBEL R, TORTORIELLO D V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity[J]. Endocrinology, 2008, 149:3549-3558.
[20]
RAHIMI H R, MOHAMMADPOUR A H, DASTANI M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial[J]. Avicenna J Phytomed, 2016, 6(5):567.
[21]
SATOH N, NARUSE M, USUI T, et al. Leptin-to-adiponectin ratio as a potentialatherogenic index in obese type 2 diabetic patients[J]. Diabetes Care, 2004, 27:2488-2490.
[22]
KOTANI K, SAKANE N, SAIGA K, et al. Leptin:adiponectin ratio as anatherosclerotic index in patients with type 2 diabetes:relationship of the index to carotid intima-mediathickness[J]. Diabetologia, 2005, 48:2684-2686.
[23]
ROTHENBACHER D, BRENNER H, MARZ W, et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers[J]. Eur Heart J, 2005, 26:1640-1646.
[24]
REILLY M P, IQBAL N, SCHUTTA M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes[J]. J Clin Endocrinol Metab, 2004, 89:3872-3878.
[25]
ANAND P, THOMAS S G, KUNNUMAKKARA A B, et al. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature[J]. Biochem Pharmacol, 2008, 76:1590-1611. doi: 10.1016/j.bcp.2008.08.008.
[26]
LAO C D, RUF F IN M T, NORMOLLE D, et al. Dose escalation of a curcuminoid formulation[J]. BMC Complement Alternat Med, 2006, 6:10. doi: 10.1186/1472-6882-6-10.
[27]
PANAHI Y, SAHEBKAR A, AMIRI M, et al. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind,placebo-controlled trial[J]. Br J Utrit, 2012, 108:1272-1279. doi: 10.1017/S0007114511006544.
[28]
PANAHI Y, SAHEBKAR A, PARVIN S, et al. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications[J]. Ann Clin Biochem, 2012, 49:580-588. doi: 10.1258/acb.2012.012040.
[29]
PANAHI Y, RAHIMNIA A R, SHARAFI M, et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial[J]. Phytother Res, 2014, 28:1625-1631. doi: 10.1002/ptr.5174.
[30]
SAHEBKAR A, MOHAMMADI A, ATABATI A, et al. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized ldl in obese individuals[J]. Hytother Res, 2013, 27:1883-1888. doi:10.1002/ptr.4952.
[31]
PANAHI Y, BADELI R, KARAMI G R, et al. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder[J]. Phytother Res, 2015, 29:17-21. doi: 10.1002/ptr.5211.
[32]
JANG E M, CHOI M S, JUNG U J, et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters[J]. Metabolism, 2008, 57:1576-1583.
[33]
EJAZ A, WU D, KWAN P, et al. Curcumin inhibits adipogenesis in 3 T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice[J]. J Nutr, 2009, 139:919-925.
[34]
WEISBERG S P, LEIBEL R, TORTORIELLO D V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity[J]. Endocrinology, 2008, 149:3549-3558.
[35]
ASAI A, MIYAZAWA T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue[J]. J Nutr, 2001, 131:2932-2935.
[36]
SEO K I, CHOI M S, JUNG U J, et al. Effect of curcumin supplementation on blood glucose,plasma insulin, and glucose omeostasisrelated enzyme activities in diabetic db/db mice[J]. Mol Nutr Food Res, 2008, 52: 995-1004.
[37]
BAUM L, CHEUNG S K, MOK V C, et al. Curcumin effects on blood lipid profile in a 6-month human study[J]. Pharmacol Res, 2007, 56:509-514.
[38]
RAMIREZ-BOSCA A, SOLER A, CARRION M A, et al. An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention[J]. Mech Ageing Dev, 2000, 119: 41-47.
[39]
CATAPANO A L, GRAHAM I, DE BACKER G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2016, 37(39):2999-3058.
[40]
AGUIAR C, ALEGRIA E, BONADONNA R C, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy[J]. Atheroscler Suppl, 2015, 19: 1-12.
[41]
REINER Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients:a clinical update[J]. Nutr Metabol Cardiovasc Dis NMCD, 2013, 23(9):799-807.
[42]
CHUENGSAMARN S, RATTANAMONGKOLGUL S,PHONRAT B, et al. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial[J]. J Nutr Biochem, 2014, 25 (2):144-150.
[43]
EJAZ A, WU D, KWAN P, et al. Curcumin inhibits adipogenesis in 3 T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice[J]. J Nutr, 2009, 139:919-925.
[44]
WEISBERG S P, LEIBEL R, TORTORIELLO D V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity[J]. Endocrinology, 2008, 149: 3549-3558.
[45]
ANAND P, KUNNUMAKKARA A B, NEWMAN R A, et al. Bioavailability of curcumin:problems and promises[J]. Mol Pharm, 2007, 4:807-818. doi: 10.1021/mp700113r.
[46]
SHOBA G, JOY D, JOSEPH T, et al. Inf luence of piperine on the phar-macokinetics of curcumin in animals and human volunteers[J]. Planta Med, 1998, 64:353-356.
2021, Vol. 56 
